Clinical Trials
-
Principal Investigator:
Sloane Heller, MDThe purpose of this study is to understand how liver disease affects thinking and memory, both before and after transplant. Participants will take a cognitive test, which will be a series of tasks and questions similar to a video game, at home on their own computers, tablets, or phones. This will take approximately 45 minutes, and participants will do this once a year for 3 years. We will assess how thinking and memory changes over time and in response to transplant. -
Principal Investigator:
Rebecca Straus Farber, MDWe need your help today to gather information about the experience of patients with autoimmune diseases of the central nervous system (multiple sclerosis (MS), neuromyelitis optica (NMO), and antiMOG associated disease (MOGAD)) in regards to COVID-19 vaccines. Because individuals with MS, NMO, and MOGAD were not included in the COVID-19 vaccine trials, we want to learn more about the experience of individuals with these autoimmune diseases and the vaccine. Because many patients with central nervous system autoimmune disease also take medications that affect the immune system, we want to find... -
Principal Investigator:
Philip L. De Jager, MD, PHDThe Snapshot study aims to understand brain and spinal cord aging in healthy individuals and individuals with multiple sclerosis (MS). We aim to identify new tools that will help us to achieve successful brain aging in the general population and in people with an underlying autoimmune disease. A critical aspect of this study is that we are looking for individuals who are willing to donate their brain and spinal cord when they pass away; this will enable the investigators to understand which molecules in the brain made someone more or less likely to age successfully. The brains will be housed... -
Principal Investigator:
Sheng-Han Kuo, MDWhy? By investigating individuals with SCA, we will gain valuable insights into the specific mechanisms through which the cerebellum participates in cognitive processes. Who? Healthy adults over the age of 18, who would like to participate as controls. What? Participation involves one clinic visit for 3-4 Hours, involving cognitive baseline measurements, an electroencephalography (EEG) and functional magnetic resonance imaging (fMRI) recording during which a decision-making two-step task will be performed. Cost to me? There is no cost involved for participating in the study. You will receive... -
Principal Investigator:
Philip L. De Jager, MD, PHDThe Snapshot study aims to understand brain and spinal cord aging in healthy individuals and individuals with multiple sclerosis (MS). We aim to identify new tools that will help us to achieve successful brain aging in the general population and in people with an underlying autoimmune disease. A critical aspect of this study is that we are looking for individuals who are willing to donate their brain and spinal cord when they pass away; this will enable the investigators to understand which molecules in the brain made someone more or less likely to age successfully. The brains will be housed... -
Principal Investigator:
Philip L. De Jager, MD, PHDMS Genetics aims to better understand the genetic component of demyelinating diseases by doing genetic testing on blood samples of participants. This study involves a one-time blood draw and completion of questionnaires spread out over a couple of years in hopes to better understand the genes that makes one predisposed to Multiple Sclerosis and various other demyelinating diseases. -
Principal Investigator:
Christiane Reitz, MD, PhDWe are recruiting families with members under the age of 65 who have dementia or are experiencing memory problems. Our initial screening can be completed in person or over the phone. The evaluation will take about 1 to 1.5 hours per person and includes a: 1. Blood sample (5 tablespoons) or saliva (1 teaspoon) collection: These blood samples will allow us to examine genes to identify causative mutations. 2. Brief Neuropsychological Assessment. 3. Medical History: A research physician will collect basic medical information on you and your family. This assessment will provide information on... -
Principal Investigator:
Jennifer M. Bain, MD, PhDThis is a Phase IIA Multicenter, open-label, 12-week study to investigate the pharmacokinetics and safety and to provide proof of mechanism of the drug, Alogabat (RO7017773) in children and adolescents aged 5-17 years old with Angelman Syndrome with the deletion genotype. -
Principal Investigator:
Sheng-Han Kuo, MDYou may be eligible to take part in the study because you have a diagnosis of Multiple System Atrophy (MSA) with the symptoms of neurogenic Orthostatic Hypotension (nOH). MSA is a rare disorder in adults that progresses rapidly and ultimately is a fatal neurodegenerative disease. It is characterized by autonomic failure affecting blood pressure regulation, movement and balance. Autonomic failure occurs when the autonomic nervous system, which controls functions responsible for well-being and maintaining balance, does not regulate properly. The main purpose of this study is to look at... -
Principal Investigator:
Maria Diaz Ordonez, MDThe main purpose of this study is to determine a dose of AZD9574 that is safe and tolerable (does not cause side effects that could prevent people from taking the drug) when given alone or in combination with temozolomide. The study will also evaluate how much of the study drug is in your blood at various times. In addition, the action of the study drug will be evaluated by measuring specific chemicals in the blood. All parts of this study are experimental which means AZD9574 is not approved by the U.S. Food and Drug Administration (FDA). This is the first time AZD9574 has been tested in...